Loading
A phase 1/2 trial of Trastuzumab pamirtecan and Pertuzumab in advanced solid tumours, run by DualityBio Inc., now recruiting.
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05150691 by DualityBio Inc., with 796 participants planned, started 2022-01-31 and due to reach its primary completion in 2027-08. Interventions recorded: DB-1303/BNT323, Pertuzumab Injection, Ritonavir and Itraconazole.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab pamirtecan, Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/